July 14, 2020 C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM Challenge TUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team f
June 23, 2020 C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19 Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio
June 20, 2020 C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan
May 13, 2020 C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nas
April 30, 2020 C-Path Appoints Two New Members to Board of Directors TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new
April 29, 2020 C-Path ePRO Consortium and PRO Consortium Announce COVID-19 Risk Assessment and Mitigation Strategies Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials. &n
April 28, 2020 C-Path Receives Letter of Support from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 28, 2020 — The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D
April 21, 2020 C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials Resulting novel drug development tools will support patient-focused drug development for children with asthma TUCSON
March 19, 2020 C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Res
March 18, 2020 C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease TUCSON, Ariz., March 18, 2020 — The Critical Path Institute (C-Path) and H. Lundbeck A/S (Lundbeck) are proud to a